Results 1 to 10 of about 20,247 (196)

IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer [PDF]

Communications Biology
Macrophages play a key role in immunity against solid tumors. However, their development and clinical applications are limited by their difficult-to-transfect nature, low proliferative capacity, and easily changing polarization states. The combination of
Yizhao Chen, Xiangling Zhu, Yu Chen, Zhaoyi Yang, Zhaolei Shen, Mengchen Chen, Chong Liu, Yuanyuan Zhou, Huihui Wang, Mengjuan Zhu, Jiaqi Qiu, Jinhua Huang, Xintong Han, Wei Wei, Li Ruilin, Wenming Hong, Jiajie Tu   +16 more
doaj   +5 more sources

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation [PDF]

OncoImmunology, 2020
Cancer cells overexpress CD47 to subvert phagocytic elimination and evade immunogenic processing of cancer antigens. Moreover, CD47 overexpression inhibits the antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) activities of ...
Wijnand Helfrich, Mark Hendriks, Douwe Freerk Samplonius   +2 more
exaly   +4 more sources

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

Molecular Therapy, 2021
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a ubiquitously expressed innate immune checkpoint that promotes evasion of tumors from immune surveillance.
Jianhua Sui, Yonghe Qi, Kaixin Du
exaly   +3 more sources

CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion

Frontiers in Immunology
Red blood cell (RBC) alloantibodies can result in the rapid removal of incompatible RBCs following transfusion. However, antibody-mediated clearance of RBCs is not the inevitable outcome of an incompatible transfusion. Antibody engagement can also result
Ryan P. Jajosky, Ryan P. Jajosky, Mischa L. Covington, Mischa L. Covington, Jun Liu, Jun Liu, Li Chai, Patricia E. Zerra, Patricia E. Zerra, Patricia E. Zerra, Satheesh Chonat, Satheesh Chonat, Sean R. Stowell, Sean R. Stowell, Connie M. Arthur, Connie M. Arthur   +15 more
doaj   +3 more sources

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells [PDF]

MAbs, 2015
Agents that block the anti-phagocytic signal CD47 can synergize with pro-phagocytic anti-tumor antigen antibodies to potently eliminate tumors. While CD47 is overexpressed on cancer cells, its expression in many normal tissues may create an 'antigen sink' that could minimize the therapeutic efficacy of CD47 blocking agents.
Cyndhavi Narayanan, Ravindra Majeti, Christine E Ryan   +2 more
exaly   +3 more sources

CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma. [PDF]

PLoS ONE
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa
Abdula Monther, Riyam Al-Msari, Robert Saddawi-Konefka, Santiago Fassardi, Cynthia Tang, Chad Philips, Prakriti Sen, Pardis Mohammadzadeh, Kelsey Decker, Sayuri Miyauchi, Souvick Roy, Riley Jones, Xingyu Wu, Silvio Gutkind, Andrew Sharabi, Joseph Califano   +15 more
doaj   +2 more sources

PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses

International Journal of Nanomedicine, 2019
Shilong Song, Xiaoxiao Jin, Lei Zhang, Chen Zhao, Yan Ding, Qianqian Ang, Odontuya Khaidav, Chuanlai Shen Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of China
Song S, Jin X, Zhang L, Zhao C, Ding Y, Ang Q, Khaidav O, Shen C   +7 more
doaj   +5 more sources

SIRPα ablated iPSC-derived macrophages resist hypophagia and enhance mAb-dependent and CAR-mediated cytotoxicity of solid tumors [PDF]

Molecular Therapy: Oncology
The SIRPα-CD47 “don’t eat me” checkpoint axis plays a critical role in shaping antitumor activities of macrophages within the tumor microenvironment (TME).
Portia R. Smith, Md Ehsanul Kabir, Jue Zhang, John P. Maufort, Matthew H. Forsberg, Divine M. Sedzro, Mark Berres, James A. Thomson, Christian M. Capitini, Igor I. Slukvin   +9 more
doaj   +2 more sources

CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity

Experimental Hematology and Oncology
Abstract Background Chimeric antigen receptor (CAR)-T cell therapy has shown success in hematologic malignancies but has encountered challenges in solid tumors. Macrophages, being a potentially effective therapeutic target, have led to the development of several therapeutic strategies due to their unique phagocytic ...
Ping Cheng, Su Chao, Cheng Ping
exaly   +4 more sources

Deciphering the role of CD47 in cancer immunotherapy

Journal of Advanced Research
Background: Immunotherapy has emerged as a novel strategy for cancer treatment following surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric antigen receptor (CAR)-T cell therapies have been successful in clinical trials ...
Yufeng Shi, Lan Fang, Yu'E Liu
exaly   +3 more sources